{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122309","form_type":"8-K","ticker":"SEER","cik":"0001726445","company_name":"Seer, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.376542+00:00","generated_at":"2026-05-30T04:40:47.890825+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Seer Q3 2024 revenue $4.0M, net loss $21.3M; FY guidance reaffirmed $13-15M","bullets":["Q3 revenue $4.0M vs $4.2M YoY (down 3%); product revenue $3.1M, service $847K, grant $90K.","Net loss $21.3M vs $21.1M YoY; gross margin 48%; operating expenses down 6% to $26.3M.","Repurchased 3.7M shares at avg $1.78 in Q3; total 5.7M shares repurchased to date.","Entered co-marketing agreement with Thermo Fisher Scientific for Proteograph suite with Orbitrap Astral mass specs.","Cash, equivalents & investments $312M; FY 2024 revenue guidance reaffirmed at $13-15M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122309","json":"https://secwatch.observer/filing/0000950170-24-122309.json","markdown":"https://secwatch.observer/filing/0000950170-24-122309.md","text":"https://secwatch.observer/filing/0000950170-24-122309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726445/000095017024122309/0000950170-24-122309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726445/000095017024122309/ck0001726445-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:40:47.890825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}